Abstract: Cervical cancer is the forth most common female cancer in the world, and it is developing in a younger trend. Therefore, early diagnosis and treatment is very important. MicroRNAs (miRNAs) are conserved, single-stranded, non-coding small RNAs composed of 19-23 nucleotides. MiRNAs have been shown to be abnormally expressed in many human cancers, and they play an important role in the development, progression and metastasis of cancer. As a highly conserved miRNA, miR-375 is present on human chromosome 2 and has been shown to be down-regulated in cervical cancer patients. It is involved in the progression of cervical cancer by regulating the expression of downstream target genes. The sensitivity and specificity of serum miR-375 are superior to the traditional tumor marker CA125. The sensitivity is better than that of liquid-based cytology (TCT). MiR-375 is expected to be a new marker for early diagnosis of cervical cancer. MiR-375 can regulate the sensitivity of chemoradiotherapy for cervical cancer, and it can be used as a potential effective drug target. Loss of expression of miR-375 promotes the occurrence of cervical cancer, and it is also an important factor to promote the progression of clinical stage or the risk of recurrence. MiR-375 can be used as a biomarker for predicting the prognosis of cervical cancer. In this article, we focus on the mechanism of miR-375 in the progression of cervical cancer and its clinical diagnosis and prognosis.

Key words: MicroRNAs;, Uterine cervical neoplasms;, Cervical intraepithelial neoplasia;, Cell proliferation, Apoptosis